On May 25, 2025, Polaris Pharmaceuticals-KY announced the restructuring of its US subsidiaries, DesigneRx Pharmaceuticals, Inc. (DRx) in Northern California and Polaris Pharmaceuticals, Inc. (PPI) in Southern California. The board approved this optimization to improve operational efficiency and reduce fixed costs, focusing resources on core business and key product development. This adjustment will not affect the core functions or ongoing product development of the subsidiaries.
FACT BOX
- Source: PR Times
- Category: corporate_restructuring
- Organizations: DesigneRx Pharmaceuticals / Polaris Pharmaceuticals